Patel M, Jain J, Tohen M, et al. - In this post hoc analyses of data from three randomized, double-blind, placebo-controlled trials, researchers evaluated the effectiveness of cariprazine in bipolar I depression patient subgroups defined by baseline demographic and clinical features. Per findings, all patient subgroups had consistent improvement in depressive symptoms in correlation with receiving cariprazine 1.5–3 mg/d regardless of disparities in baseline demographic and clinical characteristics, indicating broad efficacy across a spectrum of patients with bipolar I depression. The least-squares mean difference in MADRS total score change from baseline was statistically significant for cariprazine 1.5–3 mg/d vs placebo in all patient subgroups analyzed: demographic characteristics (age, sex, white or black race and obese/nonobese BMI); episode characteristics (defined by current episode duration, number of previous manic/mixed and depressive episodes, and prior bipolar disorder medication use) and disease severity (groups above and below Clinical Global Impressions-Severity and MADRS cutoff scores).